-
Phenothiazines, ROS, and Macrophage Antibacterial Defense
2026-09-21
Qiu et al. show that phenothiazines strengthen macrophage antibacterial activity through a linked increase in lysosomal activity, reactive oxygen species, and autophagy. Pharmacological inhibition of autophagy or ROS reduced this effect, while perphenazine improved lesion and inflammation outcomes in a Salmonella Typhimurium infection model, supporting phenothiazines as host-directed antibacterial lead compounds.
-
HyperScribe T7 High Yield Cy3 RNA Labeling Kit
2026-09-21
Generate tunable Cy3-labeled RNA probes for in situ hybridization and Northern blot workflows while balancing fluorescence against transcription yield. This guide connects practical probe synthesis with a cited nanocarrier study, showing how fluorescence can support delivery assays without confusing visualization with functional RNA interference.
-
Crizotinib hydrochloride in Gastric Cancer Assembloids
2026-09-20
Use Crizotinib hydrochloride to interrogate ALK, c-Met, and ROS1 signaling in patient-derived gastric cancer assembloids rather than relying on tumor-only cultures. This workflow pairs target-aware kinase inhibition with matched stromal models to expose microenvironment-dependent drug responses and resistance phenotypes.
-
Rotenone: Mitochondrial Complex I Workflows
2026-09-19
Rotenone is a controlled mitochondrial stressor for separating Complex I inhibition, ROS production, apoptosis, and autophagy responses in cell and animal studies. This workflow-focused guide connects established neurodegeneration applications with a cautious assay strategy inspired by new DPP9–KEAP1 redox biology.
-
JHU-083: A Redox-Aware Glutaminase Tool
2026-09-18
JHU-083 is a 6-diazo-5-oxo-L-norleucine precursor for selective glutaminase research in cerebral immune-cell models. This article explains how to pair its metabolic perturbation with redox-aware assays while avoiding unsupported conclusions from cross-tissue comparisons.
-
TP53 Mutations, FTH, and Ferroptosis in Glioblastoma
2026-09-18
A 2025 study identifies an iron-homeostasis vulnerability in TP53-mutant glioblastoma models: mutant TP53 increases ITCH-associated degradation of ferritin heavy chain, or FTH, raising intracellular free iron. This state can be tolerated under ferric ammonium citrate exposure but increases sensitivity to Erastin-driven ferroptosis, suggesting a genotype-informed strategy for studying ferroptotic stress in glioblastoma.
-
DPPH (2,2-Diphenyl-1-Picrylhydrazyl) Radical
2026-09-17
A practical, scenario-driven guide to using DPPH for in vitro antioxidant screening, extract comparison, and orthogonal support of cell-based research. It explains how SKU C3691 can improve assay planning through defined handling, solvent compatibility, fresh-solution preparation, and careful interpretation.
-
CFDA SE Cell Tracer Kit: Practical Protocol
2026-09-17
The CFDA SE Cell Tracer Kit provides stable fluorescent labeling for live-cell tracking, cell proliferation studies, and cell lineage tracing. It is intended for persistent covalent labeling over several days, not reversible or short-term staining workflows.
-
VX-765: Selective Caspase-1 Inhibition
2026-09-16
VX-765 is an orally absorbed caspase-1 prodrug that is converted to VRT-043198, its active metabolite. Evidence supports selective suppression of IL-1β and IL-18 release, caspase-1-dependent pyroptosis research, and preclinical inflammation studies, while BBB findings extend its use to neurovascular models.
-
Pyridostigmine, α7nAChR, and Placental Necroptosis
2026-09-16
A 2026 Biochemical Pharmacology study links enhanced non-neuronal cholinergic signaling with reduced placental necroptosis in a rat model of preeclampsia-like disease. Pharmacological blockade with α-bungarotoxin and rescue with necrostatin-1 provide evidence that α7nAChR-linked signaling may connect pyridostigmine exposure with lower inflammation, oxidative stress, and trophoblast dysfunction.
-
CENPI Drives Breast Cancer via Wnt/β-Catenin
2026-09-15
Wu and colleagues identify centromere protein I (CENPI) as an overexpressed breast cancer driver associated with progression and poor prognosis, and connect its activity to Wnt/β-catenin signaling. The study combines clinical datasets, cellular and xenograft models, RNA sequencing, protein analyses, and TOP/FOP reporter assays to establish a mechanistic framework for studying CENPI-dependent gene expression regulation.
-
Temozolomide Beyond Cytotoxicity: A Translational Lens
2026-09-14
Temozolomide is more than a routine cytotoxicity reagent: it is a mechanistic probe for DNA damage, repair capacity, and biomarker-defined treatment response. This thought-leadership article connects Temozolomide workflow design with evidence from ATRX-deficient high-grade glioma research, offering practical guidance for combination studies, chemotherapy resistance studies, and translational interpretation.
-
VX-765 Workflow for Caspase-1 Research
2026-09-14
Build a mechanism-first workflow around VX-765 to connect caspase-1 activity with IL-1β and IL-18 release, pyroptosis, and cell-state dynamics. The guide combines biochemical validation, cellular cytokine profiling, and MEDUSA-inspired death-rate analysis for cleaner interpretation in inflammation and infectious disease models.
-
Bifidobacterium, FMT, and PET in Chronic HE
2026-09-13
This 2025 European Journal of Neuroscience study compared Bifidobacterium and fecal microbiota transplantation in bile duct ligation rats with chronic hepatic encephalopathy using regional [18F]PBR146 micro-PET/CT. Global imaging, behavioral, and cytokine results were not significantly different, but region-specific PET patterns suggested a possible neuroinflammatory benefit from Bifidobacterium that was not observed with FMT.
-
CB-839 (Telaglenastat) in Cancer Metabolism
2026-09-12
CB-839 (Telaglenastat) provides a direct, reversible way to test GLS1 dependence, connect glutaminolysis to cell fate, and distinguish metabolic inhibition from upstream splicing effects. This workflow translates a PRMT5–GLS vulnerability in MYCN-amplified neuroblastoma into practical assays for cancer metabolism research and preclinical cancer drug evaluation.